Detalles de la búsqueda
1.
Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors.
Bioorg Med Chem Lett
; 27(13): 3030-3035, 2017 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28526367
2.
Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4H-chromen-4-one as PI3Kß/δ inhibitors for the treatment of PTEN-deficient tumours.
Bioorg Med Chem Lett
; 27(9): 1949-1954, 2017 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28347666
3.
Discovery of a series of 8-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-2-morpholino-4-oxo-chromene-6-carboxamides as PI3Kß/δ inhibitors for the treatment of PTEN-deficient tumours.
Bioorg Med Chem Lett
; 26(9): 2318-23, 2016 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26996374
4.
Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers.
Bioorg Med Chem Lett
; 25(22): 5155-62, 2015 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26475521
5.
Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kß/δ inhibitors for the treatment of PTEN-deficient tumours.
Bioorg Med Chem Lett
; 24(16): 3928-35, 2014 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24992874
6.
Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer.
Bioorg Med Chem Lett
; 21(18): 5442-5, 2011 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21782422
7.
Synthesis and structure-activity relationships of thieno[2,3-b]pyrroles as antagonists of the GnRH receptor.
Bioorg Med Chem Lett
; 17(23): 6448-54, 2007 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17937987
8.
The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
PLoS One
; 12(8): e0183048, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28806782
9.
Inhibiting PI3Kß with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors.
Clin Cancer Res
; 23(24): 7584-7595, 2017 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28972046
10.
The use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kß/δ inhibitor.
EJNMMI Res
; 6(1): 62, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27515445
11.
Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.
Mol Cancer Ther
; 15(5): 877-89, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26839307
12.
Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kß and PI3Kδ for the treatment of PTEN-deficient cancers.
J Med Chem
; 58(2): 943-62, 2015 Jan 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-25514658
13.
Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kß.
Cancer Cell
; 27(1): 109-22, 2015 Jan 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-25544636
14.
Inhibition of PI3Kß signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
Mol Cancer Ther
; 14(1): 48-58, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25398829
Resultados
1 -
14
de 14
1
Próxima >
>>